Cargando…
Drug tendering: drug supply and shortage implications for the uptake of biosimilars
Due to the continued increase in global spending on health care, payers have introduced a number of programs, policies, and agreements on pharmaceutical pricing in order to control costs. While incentives to increase generic drug use have achieved significant savings, other cost-containment measures...
Autores principales: | Dranitsaris, George, Jacobs, Ira, Kirchhoff, Carol, Popovian, Robert, Shane, Lesley G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628685/ https://www.ncbi.nlm.nih.gov/pubmed/29033595 http://dx.doi.org/10.2147/CEOR.S140063 |
Ejemplares similares
-
Development of biosimilars in an era of oncologic drug shortages
por: Li, Edward, et al.
Publicado: (2015) -
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
por: Simoens, Steven, et al.
Publicado: (2017) -
Can biosimilars help achieve the goals of US health care reform?
por: Boccia, Ralph, et al.
Publicado: (2017) -
Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
por: Jacobs, Ira, et al.
Publicado: (2016) -
Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future
por: Carrascosa, Jose-Manuel, et al.
Publicado: (2018)